|
CTNNA1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.59919982706458E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.25929999761354E-09 |
| Normal-vs-Stage2 |
1.135260E-03 |
| Normal-vs-Stage3 |
9.52269999965338E-07 |
| Normal-vs-Stage4 |
1.4317999996738E-07 |
| Stage1-vs-Stage2 |
6.617800E-01 |
| Stage1-vs-Stage3 |
6.135800E-01 |
| Stage1-vs-Stage4 |
5.768600E-01 |
| Stage2-vs-Stage3 |
9.452400E-01 |
| Stage2-vs-Stage4 |
4.775000E-01 |
| Stage3-vs-Stage4 |
4.080000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.90570053865736E-10 |
| Normal-vs-AfricanAmerican |
4.248300E-04 |
| Normal-vs-Asian |
2.42180000498138E-08 |
| Caucasian-vs-AfricanAmerican |
3.854200E-01 |
| Caucasian-vs-Asian |
2.709200E-01 |
| AfricanAmerican-vs-Asian |
9.556800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.8127999979487E-08 |
| Normal-vs-Female |
9.13150000059204E-10 |
| Male-vs-Female |
8.481200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.9725999722553E-09 |
| Normal-vs-Age(41-60Yrs) |
6.20129947392911E-10 |
| Normal-vs-Age(61-80Yrs) |
8.624300E-04 |
| Normal-vs-Age(81-100Yrs) |
6.077600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.956400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.475900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.198000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.868480E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.124000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.193400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.092800E-01 |
| Classical-VS-Follicular |
2.83717493942959E-12 |
| Classical-VS-Other |
2.529400E-01 |
| Classical-VS-Normal |
1.81432646684243E-12 |
| Tall-VS-Follicular |
2.34619999994745E-06 |
| Tall-VS-Other |
1.991160E-01 |
| Tall-VS-Normal |
2.69240000294602E-08 |
| Follicular-VS-Other |
2.715800E-01 |
| Follicular-VS-Normal |
4.825600E-01 |
| Other-VS-Normal |
6.699900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.90062999999574E-05 |
| Normal-vs-N1 |
4.797700E-04 |
| N0-vs-N1 |
7.236600E-01 |
|
|
